Aligos Therapeutics (ALGS) Total Liabilities (2019 - 2026)

Aligos Therapeutics has reported Total Liabilities for 8 years, with the latest figure at $32.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 4.34% year-over-year to $32.8 million; the trailing twelve-month figure through Mar 2026 stood at $32.8 million (down 4.34% YoY), and the FY2025 full-year result was $35.0 million, down 64.68% from the prior year.
• Total Liabilities for Q1 2026 stood at $32.8 million, down from $35.0 million in the prior quarter.
• The five-year high for Total Liabilities was $99.1 million in Q4 2024, with the low at $31.0 million in Q3 2023.
• Historically, Total Liabilities has averaged $45.4 million across 5 years, with a median of $38.3 million in 2024.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 84.13% — and 2025, when it sank 64.68%.
• Aligos Therapeutics' Total Liabilities stood at $42.8 million in 2022, then surged by 38.92% to $59.4 million in 2023, then jumped by 66.65% to $99.1 million in 2024, then sank by 64.68% to $35.0 million in 2025, then declined by 6.34% to $32.8 million in 2026.
• The last three Total Liabilities figures came in at $32.8 million (Q1 2026), $35.0 million (Q4 2025), and $37.9 million (Q3 2025), per Business Quant data.